A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors
Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Dec 28, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging agent called 68Ga-DOTA-GPFAPI-04, which is designed to help doctors see and identify various types of cancer more clearly. This agent targets a specific protein found in many tumors, allowing for better imaging during a procedure called positron emission tomography (PET). The aim is to improve the accuracy of detecting malignant tumors, especially in patients who may have already had a cancer diagnosis or are suspected of having a recurrence.
To be eligible for this trial, participants should be adults aged 18 or older who have a strong suspicion of having malignant tumors, based on previous biopsies. They should not have received chemotherapy or radiation therapy in the last three months and must be willing to undergo a biopsy or surgery if necessary. If you choose to participate, you can expect to undergo imaging tests and follow-up exams to monitor your health throughout the study. This research could lead to better ways to diagnose and treat cancer, so your involvement could help advance medical knowledge and patient care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with high clinical suspicion of malignant tumors;
- • 2. Those who have undergone endoscopic biopsy or puncture biopsy indicating malignant tumors but have not undergone surgery or chemotherapy;
- • 3. Previous history of malignant tumor surgery, suspected of recurrence or distant metastasis;
- • 4. There is a willingness for puncture biopsy or surgery, and there are no contraindications for puncture biopsy or surgery, and there are no contraindications for anesthesia;
- • 5. Sign an informed consent form and undergo a nuclear medicine examination, without any contraindications, with the ability and willingness to participate in the follow-up plan.
- Exclusion Criteria:
- • 1. Those who cannot tolerate puncture biopsy or surgical contraindications;
- • 2. Those who have undergone radiotherapy and chemotherapy in the past 3 months;
- • 3. Individuals who are allergic to multiple drugs or foods;
- • 4. Those who refuse nuclear medicine examinations;
- • 5. Those who do not agree to sign an informed consent form and are unable or willing to follow up.
About Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital is a leading tertiary healthcare institution located in Guangdong Province, China, renowned for its comprehensive medical services and advanced research capabilities. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical science through innovative research and the rigorous evaluation of new therapies and interventions. With a multidisciplinary team of experienced clinicians and researchers, the institution prioritizes patient safety and ethical standards while fostering collaborations with academic and industry partners to enhance healthcare outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported